Literature DB >> 25657311

Sex differences in platelet toll-like receptors and their association with cardiovascular risk factors.

Milka Koupenova1, Eric Mick2, Ekaterina Mikhalev2, Emelia J Benjamin2, Kahraman Tanriverdi2, Jane E Freedman2.   

Abstract

OBJECTIVE: Platelets contribute to thrombosis, and platelet toll-like receptors (TLRs) are central in pathogen detection, potentially mediating infection-induced vascular occlusion. Using a large community-based cohort study, we sought to examine if platelets express all known TLR transcripts and analyze their association with cardiovascular risk factors. APPROACH AND
RESULTS: mRNA levels for TLRs were measured in isolated platelets by high-throughput quantitative reverse transcriptase polymerase chain reaction in 1625 participants (mean age, 66.6±9; 54% women) of the Framingham Heart Study. We measured circulating inflammatory and thrombotic markers (C-reactive protein, interleukin-6, monocyte chemoattractant protein 1, intracellular cell adhesion molecule 1, soluble tumor necrosis factor-α receptor 1, and soluble p-selectin) and analyzed TLRs and their association with sex and cardiovascular risk factors by multivariable logit regression model adjusted for confounding factors. Platelets expressed all 10 TLR transcripts, and all TLRs were coexpressed. Women had higher platelet TLR expression, which associated with different cardiovascular risk factors, compared with men. In women, TLR1, TLR3, TLR6, and TLR7 were associated with body mass index and TLR5, TLR7, and TLR10 were associated with total cholesterol to high-density lipoprotein ratio. In men, TLR1, TLR2, and TLR3 were associated with lipid and TLR8 with hypertension treatment. Similarly, TLR expression in men was more commonly associated with circulating inflammatory markers (soluble tumor necrosis factor-α receptor 1 and intracellular cell adhesion molecule 1), whereas in women, TLR expression was associated with soluble p-selectin levels.
CONCLUSIONS: We report the first study to demonstrate that platelets express all TLR transcripts using a large community-based observational cohort. These transcripts are more abundant in women and have distinct associations with cardiovascular risk and inflammatory biomarkers that vary by sex.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  blood platelets; epidemiology; infection; inflammation

Mesh:

Substances:

Year:  2015        PMID: 25657311      PMCID: PMC4376646          DOI: 10.1161/ATVBAHA.114.304954

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  30 in total

1.  Platelets express functional Toll-like receptor-4.

Authors:  Graciela Andonegui; Steven M Kerfoot; Kelly McNagny; Kirsten V J Ebbert; Kamala D Patel; Paul Kubes
Journal:  Blood       Date:  2005-06-16       Impact factor: 22.113

2.  Genome-wide RNA-seq analysis of human and mouse platelet transcriptomes.

Authors:  Jesse W Rowley; Andrew J Oler; Neal D Tolley; Benjamin N Hunter; Elizabeth N Low; David A Nix; Christian C Yost; Guy A Zimmerman; Andrew S Weyrich
Journal:  Blood       Date:  2011-05-19       Impact factor: 22.113

3.  Sex-dependent differences in plasma cytokine responses to hantavirus infection.

Authors:  Jonas Klingström; Therese Lindgren; Clas Ahlm
Journal:  Clin Vaccine Immunol       Date:  2008-03-19

4.  Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial.

Authors:  James A de Lemos; David A Morrow; Michael A Blazing; Petr Jarolim; Stephen D Wiviott; Marc S Sabatine; Robert M Califf; Eugene Braunwald
Journal:  J Am Coll Cardiol       Date:  2007-11-13       Impact factor: 24.094

5.  Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia.

Authors:  M G Netea; A Hijmans; S van Wissen; T J Smilde; M D Trip; B J Kullberg; T de Boo; J W M Van der Meer; J J P Kastelein; A F H Stalenhoef; A F H Stalenhorf
Journal:  Eur J Clin Invest       Date:  2004-02       Impact factor: 4.686

6.  Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase.

Authors:  Price Blair; Sybille Rex; Olga Vitseva; Lea Beaulieu; Kahraman Tanriverdi; Subrata Chakrabarti; Chie Hayashi; Caroline A Genco; Mark Iafrati; Jane E Freedman
Journal:  Circ Res       Date:  2008-12-23       Impact factor: 17.367

7.  Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study.

Authors:  E L Barrett-Connor; B A Cohn; D L Wingard; S L Edelstein
Journal:  JAMA       Date:  1991-02-06       Impact factor: 56.272

8.  Association of hypo-responsive toll-like receptor 4 variants with risk of myocardial infarction.

Authors:  Kristina Edfeldt; Anna M Bennet; Per Eriksson; Johan Frostegård; Björn Wiman; Anders Hamsten; Göran K Hansson; Ulf de Faire; Zhong-qun Yan
Journal:  Eur Heart J       Date:  2004-08       Impact factor: 29.983

9.  Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.

Authors:  Salim Yusuf; Steven Hawken; Stephanie Ounpuu; Tony Dans; Alvaro Avezum; Fernando Lanas; Matthew McQueen; Andrzej Budaj; Prem Pais; John Varigos; Liu Lisheng
Journal:  Lancet       Date:  2004 Sep 11-17       Impact factor: 79.321

Review 10.  The X-files in immunity: sex-based differences predispose immune responses.

Authors:  Eleanor N Fish
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

View more
  48 in total

1.  Expression of TLR2, NOD1, and NOD2 and the NLRP3 Inflammasome in Renal Tubular Epithelial Cells of Male versus Female Mice.

Authors:  Sean E DeWolf; Alana A Shigeoka; Andrew Scheinok; Sashi G Kasimsetty; Alexander K Welch; Dianne B McKay
Journal:  Nephron       Date:  2017-06-15       Impact factor: 2.847

Review 2.  Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches.

Authors:  Teemu J Niiranen; Ramachandran S Vasan
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-04-25

Review 3.  Normal platelet function.

Authors:  Michael Holinstat
Journal:  Cancer Metastasis Rev       Date:  2017-06       Impact factor: 9.264

Review 4.  Short chain fatty acids and methylamines produced by gut microbiota as mediators and markers in the circulatory system.

Authors:  Maksymilian Onyszkiewicz; Kinga Jaworska; Marcin Ufnal
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-16

Review 5.  The Role of Toll-like Receptors in Atherothrombotic Cardiovascular Disease.

Authors:  Ying Zhou; Peter J Little; Liam Downey; Rizwana Afroz; Yuao Wu; Hang T Ta; Suowen Xu; Danielle Kamato
Journal:  ACS Pharmacol Transl Sci       Date:  2020-02-06

Review 6.  Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases.

Authors:  Jennifer Yeung; Wenjie Li; Michael Holinstat
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 7.  Toll-Like Receptors Contribute to Sex Differences in Blood Pressure Regulation.

Authors:  Vanessa Dela Justina; Fernanda R Giachini; Jennifer C Sullivan; R Clinton Webb
Journal:  J Cardiovasc Pharmacol       Date:  2020-09       Impact factor: 3.105

Review 8.  The non-haemostatic role of platelets in systemic lupus erythematosus.

Authors:  Petrus Linge; Paul R Fortin; Christian Lood; Anders A Bengtsson; Eric Boilard
Journal:  Nat Rev Rheumatol       Date:  2018-03-21       Impact factor: 20.543

Review 9.  T-cell involvement in sex differences in blood pressure control.

Authors:  G Ryan Crislip; Jennifer C Sullivan
Journal:  Clin Sci (Lond)       Date:  2016-05-01       Impact factor: 6.124

10.  Impact of TLR5 rs5744174 on stroke risk, gene expression and on inflammatory cytokines, and lipid levels in stroke patients.

Authors:  Lian Gu; Jingyan Huang; Jinjing Tan; Qiugui Wei; Haiyun Jiang; Tingting Shen; Baoyun Liang; Nong Tang
Journal:  Neurol Sci       Date:  2016-06-04       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.